Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRAF-Mutated Melanoma”

130 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 130 results

Not applicableActive Not RecruitingNCT07022457
What this trial is testing

UK ENcorafenib and BInimetinib Real-world Study in Melanoma

Who this might be right for
Metastatic Melanoma, BRAF V600 Mutation Positive
Pierre Fabre Ltd 50
Early research (Phase 1)Study completedNCT01673737
What this trial is testing

A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer

Who this might be right for
Neoplasm Malignant
Sanofi 75
Testing effectiveness (Phase 2)Ended earlyNCT02974803
What this trial is testing

Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases

Who this might be right for
MelanomaBrain Metastases
Canadian Cancer Trials Group 6
Early research (Phase 1)Study completedNCT01657591
What this trial is testing

Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma

Who this might be right for
Melanoma
H. Lee Moffitt Cancer Center and Research Institute 21
Not applicableStudy completedNCT04961619
What this trial is testing

Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma.

Who this might be right for
Melanoma
Novartis Pharmaceuticals 39
Early research (Phase 1)WithdrawnNCT02357732
What this trial is testing

Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib

Who this might be right for
Metastatic Melanoma
University of Pittsburgh
Testing effectiveness (Phase 2)Ended earlyNCT01551693
What this trial is testing

STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma

Who this might be right for
Melanoma
Dana-Farber Cancer Institute 3
Early research (Phase 1)Study completedNCT01656642
What this trial is testing

A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma

Who this might be right for
Malignant Melanoma
Genentech, Inc. 67
Early research (Phase 1)Ended earlyNCT01611675
What this trial is testing

Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma

Who this might be right for
Melanoma
Massachusetts General Hospital 3
Early research (Phase 1)UnknownNCT05103891
What this trial is testing

Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations

Who this might be right for
MelanomaBRAF V600 MutationUnresectable Melanoma+1 more
Pierre Fabre Medicament 14
Large-scale testing (Phase 3)Study completedNCT01597908
What this trial is testing

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Who this might be right for
Melanoma
Novartis Pharmaceuticals 704
Not applicableStudy completedNCT02310451
What this trial is testing

Study of Molecular Mechanisms Implicated in the Pathogenesis of Melanoma. Role of Exosomes

Who this might be right for
Metastatic Melanoma
Centre Hospitalier Universitaire de Nice 15
Early research (Phase 1)Study completedNCT02027961
What this trial is testing

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

Who this might be right for
Melanoma
MedImmune LLC 68
Testing effectiveness (Phase 2)Active Not RecruitingNCT03235245
What this trial is testing

Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib

Who this might be right for
Unresectable Stage III MelanomaStage IV Melanoma
European Organisation for Research and Treatment of Cancer - EORTC 271
Early research (Phase 1)Ended earlyNCT02313012
What this trial is testing

Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors

Who this might be right for
Neoplasm Metastasis
Celgene 19
Early research (Phase 1)Study completedNCT01351103
What this trial is testing

LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Who this might be right for
Pancreatic CancerBRAF Mutant Colorectal CancerMelanoma+5 more
Novartis Pharmaceuticals 185
Large-scale testing (Phase 3)Study completedNCT01689519
What this trial is testing

A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma

Who this might be right for
Malignant Melanoma
Hoffmann-La Roche 495
Large-scale testing (Phase 3)Ended earlyNCT02967692
What this trial is testing

The Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma

Who this might be right for
Melanoma
Novartis Pharmaceuticals 568
Early research (Phase 1)WithdrawnNCT02145910
What this trial is testing

Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases

Who this might be right for
Recurrent MelanomaStage IV MelanomaTumors Metastatic to Brain
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Testing effectiveness (Phase 2)Study completedNCT02836548
What this trial is testing

HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma

Who this might be right for
MelanomaSkin Neoplasms
The Netherlands Cancer Institute 33
Next Page